{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:28:13Z","timestamp":1707524893342},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"DOI":"10.7759\/cureus.34489","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T10:37:15Z","timestamp":1675247835000},"source":"Crossref","is-referenced-by-count":0,"title":["Lupus Cardiomyopathy and Nephritis Associated With Adalimumab and Cytomegalovirus Infection in a Patient With Seronegative Rheumatoid Arthritis: A Case of Rhupus Syndrome"],"prefix":"10.7759","author":[{"given":"Palapun","family":"Waitayangkoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica B","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Weins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Treadwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco C","year":"2015","unstructured":"Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015, 27:55-62. 10.1093\/intimm\/dxu102","journal-title":"Int Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals M","year":"2007","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, et al.. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007, 86:242-51. 10.1097\/MD.0b013e3181441a68","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer M","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al.. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019, 71:1400-12. 10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep080","article-title":"Anti-TNF-induced lupus","volume":"48","author":"Williams EL","year":"2009","unstructured":"Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009, 48:716-20. 10.1093\/rheumatology\/kep080","journal-title":"Rheumatology (Oxford)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12291","article-title":"Anti-TNF-induced lupus in patients with inflammatory bowel disease","volume":"4","author":"Picardo S","year":"2020","unstructured":"Picardo S, So K, Venugopal K. Anti-TNF-induced lupus in patients with inflammatory bowel disease. JGH Open. 2020, 4:507-10. 10.1002\/jgh3.12291","journal-title":"JGH Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis","volume":"20","author":"Stokes MB","year":"2005","unstructured":"Stokes MB, Foster K, Markowitz GS, et al.. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005, 20:1400-6. 10.1093\/ndt\/gfh832","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","article-title":"Nephrotic syndrome as a complication of anti-TNF\u03b1 in a patient with rheumatoid arthritis","volume":"61","author":"den Broeder AA","year":"2003","unstructured":"den Broeder AA, Assmann KJ, van Riel PL, Wetzels JF. Nephrotic syndrome as a complication of anti-TNF\u03b1 in a patient with rheumatoid arthritis. Neth J Med. 2003, 61:137-41.","journal-title":"Neth J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/812781","article-title":"Adalimumab (TNF\u03b1 inhibitor) therapy exacerbates IgA glomerulonephritis acute renal injury and induces lupus autoantibodies in a psoriasis patient","volume":"2013","author":"Wei SS","year":"2013","unstructured":"Wei SS, Sinniah R. Adalimumab (TNF\u03b1 inhibitor) therapy exacerbates IgA glomerulonephritis acute renal injury and induces lupus autoantibodies in a psoriasis patient. Case Rep Nephrol. 2013, 2013:812781. 10.1155\/2013\/812781","journal-title":"Case Rep Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals M","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008, 22:847-61. 10.1016\/j.berh.2008.09.008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2174\/187152611797636703","article-title":"Overview of the diagnosis of cytomegalovirus infection","volume":"11","author":"Ross SA","year":"2011","unstructured":"Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets. 2011, 11:466-74. 10.2174\/187152611797636703","journal-title":"Infect Disord Drug Targets"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz601","article-title":"Clinical diagnostic testing for human cytomegalovirus infections","volume":"221","author":"Razonable RR","year":"2020","unstructured":"Razonable RR, Inoue N, Pinninti SG, et al.. Clinical diagnostic testing for human cytomegalovirus infections. J Infect Dis. 2020, 221:S74-85. 10.1093\/infdis\/jiz601","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181f4cf52","article-title":"Cytomegalovirus as a trigger for systemic lupus erythematosus","volume":"16","author":"P\u00e9rez-Mercado AE","year":"2010","unstructured":"P\u00e9rez-Mercado AE, Vil\u00e1-P\u00e9rez S. Cytomegalovirus as a trigger for systemic lupus erythematosus. J Clin Rheumatol. 2010, 16:335-7. 10.1097\/RHU.0b013e3181f4cf52","journal-title":"J Clin Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/635670","article-title":"Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia","volume":"2015","author":"Barcellini W","year":"2015","unstructured":"Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers. 2015, 2015:635670. 10.1155\/2015\/635670","journal-title":"Dis Markers"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcx102","article-title":"Bone marrow involvement in systemic lupus erythematosus","volume":"110","author":"Chalayer E","year":"2017","unstructured":"Chalayer E, Costedoat-Chalumeau N, Beyne-Rauzy O, et al.. Bone marrow involvement in systemic lupus erythematosus. QJM. 2017, 110:701-11. 10.1093\/qjmed\/hcx102","journal-title":"QJM"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15691","article-title":"Liver abnormalities in systemic lupus erythematosus: a prospective observational study","volume":"13","author":"Imran S","year":"2021","unstructured":"Imran S, Thabah MM, Azharudeen M, Ramesh A, Bobby Z, Negi VS. Liver abnormalities in systemic lupus erythematosus: a prospective observational study. Cureus. 2021, 13:e15691. 10.7759\/cureus.15691","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s100670200096","article-title":"Seronegative oligoarthritis: a 23-year follow-up study","volume":"21","author":"J\u00e4ntti JK","year":"2002","unstructured":"J\u00e4ntti JK, Kaarela K, Lehtinen KE. Seronegative oligoarthritis: a 23-year follow-up study. Clin Rheumatol. 2002, 21:353-6. 10.1007\/s100670200096","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3109\/03009749309095143","article-title":"Follow-up of patients with double stranded DNA antibodies induced by sulfasalazine during the treatment of inflammatory rheumatic diseases","volume":"22","author":"Mielke H","year":"1993","unstructured":"Mielke H, Wildhagen K, Mau W, Zeidler H. Follow-up of patients with double stranded DNA antibodies induced by sulfasalazine during the treatment of inflammatory rheumatic diseases. Scand J Rheumatol. 1993, 22:299-301. 10.3109\/03009749309095143","journal-title":"Scand J Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.5.288","article-title":"Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years","volume":"58","author":"Gordon MM","year":"1999","unstructured":"Gordon MM, Porter DR, Capell HA. Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. Ann Rheum Dis. 1999, 58:288-90. 10.1136\/ard.58.5.288","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to anti-tumor necrosis factor alpha agents","volume":"37","author":"Costa MF","year":"2008","unstructured":"Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008, 37:381-7. 10.1016\/j.semarthrit.2007.08.003","journal-title":"Semin Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/ar3525","article-title":"Autoimmunity induced by human cytomegalovirus in patients with systemic lupus erythematosus","volume":"14","author":"S\u00f6derberg-Naucl\u00e9r C","year":"2012","unstructured":"S\u00f6derberg-Naucl\u00e9r C. Autoimmunity induced by human cytomegalovirus in patients with systemic lupus erythematosus. Arthritis Res Ther. 2012, 14:101. 10.1186\/ar3525","journal-title":"Arthritis Res Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/125004-lupus-cardiomyopathy-and-nephritis-associated-with-adalimumab-and-cytomegalovirus-infection-in-a-patient-with-seronegative-rheumatoid-arthritis-a-case-of-rhupus-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:41Z","timestamp":1707508181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/125004-lupus-cardiomyopathy-and-nephritis-associated-with-adalimumab-and-cytomegalovirus-infection-in-a-patient-with-seronegative-rheumatoid-arthritis-a-case-of-rhupus-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.34489","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}